All In Biotech

Free tool

FAERS Monitor: Eurax

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 006927 or its brand name (Eurax, Crotamiton). Reports on generic versions are filed under their own applications.

Reports

610

Serious

577

95% of reports

Hospitalization

261

Death reported

79

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pruritus61
  • rash44
  • pyrexia31
  • malaise27
  • anaemia26
  • pain26
  • hepatic function abnormal25
  • pneumonia23
  • diarrhoea21
  • erythema21
  • urticaria20
  • decreased appetite19
  • rash pruritic19
  • vomiting19
  • constipation18

Reports by year received

View as table
YearReports
20041
20054
200614
200719
200816
200918
201026
201120
201241
201317
201428
201546
201631
201759
201836
201930
202032
202144
202227
202325
202432
202532
202612

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,549 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatic function abnormalSignal2523.115.7508
rash pruriticSignal1912.17.8183
pruritusSignal615.54.3223
anaemiaSignal264.73.273
urticariaSignal204.12.744
erythemaSignal213.52.336
rashSignal443.52.677
pyrexiaSignal313.12.242
constipationSignal182.81.820
decreased appetiteSignal192.81.821
pneumoniaSignal232.41.619
malaiseSignal272.11.515
pain261.51.03
vomiting191.40.92
diarrhoea211.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.